Mankind Pharma Ltd

Mankind Pharma has allotted 57,709 equity shares of face value of Re. 1/- each of the Company to the eligible employees who have exercised their options pursuant to the ESOP Plan. Consequent to the aforesaid allotment, the paid-up share capital of the Company has increased from 41,26,71,039 equity shares to 41,27,28,748 equity shares having face value of Re. 1/- each. Powered by Capital Market - Live

Mankind Pharma Ltd is down for a fifth straight session today. The stock is quoting at Rs 2421, down 0.75% on the day as on 13:19 IST on the NSE. The benchmark NIFTY is up around 1.12% on the day, quoting at 24886.2. The Sensex is at 81814.38, up 1.07%.Mankind Pharma Ltd has lost around 6.86% in last one month.Meanwhile, Nifty Pharma index of which Mankind Pharma Ltd is a constituent, has eased around 2.72% in last one month and is currently quoting at 21521.75, down 0.67% on the day. The volume in the stock stood at 1.15 lakh shares today, compared to the daily average of 3.47 lakh shares in last one month.The PE of the stock is 52.01 based on TTM earnings ending December 24.Powered by Capital Market - Live

However, revenue from operations increased 27.19% year-on-year (YoY) to Rs 3,079.37 crore in the fourth quarter of FY25. Profit before tax from continuing operations was at Rs 515.43 crore in Q4 of FY25, registering a de-growth of 9.87% from Rs 571.91 crore reported in Q4 FY24. EBITDA grew 16.4% YoY to Rs 686 crore in the March 2025 quarter. EBITDA margin improved to 22.3% in Q4 FY25, compared to 24.3% recorded in the corresponding quarter previous year. Domestic revenue stood at Rs 2,544 crore in Q4 FY25, up by 18% YoY, while export revenue stood at Rs 535 crore, up by 100% YoY during the quarter. Export growth was driven by an increase in its base business supported by new launches in the last 12-24 months and consolidation of BSV. During the quarter, the company has launched 1 product in Q4 FY25 and 5 products in FY25, taking the total launched products to 44 in US. The company's consumer healthcare business reported a 14% increase in revenue to Rs 178 crore in Q4 FY25, supported by steady growth across all key brands. There was strong growth in secondary sales for Manforce Condoms, Gas-O-Fast, and HealthOK, with year-on-year increases of 17%, 29%, and 23%, respectively. The business also gained strong traction with the launches of Epic ThinX (unflavored premium category condom), Nimulid (pain management), and OvaNews (ovulation detection kit) in FY25. Rajeev Juneja, vice chairman & managing director, Mankind Pharma, said, 'Mankind's revenue grew by 27% with adjusted EBITDA margins at around 23% in Q4 FY25, led by continued 1.3x outperformance in chronic, strong growth in the consumer segment, and BSV consolidation. In FY25, reported revenue growth was 19% with an adj EBITDA margin of approximately 26%. This has been a transformative year at Mankind, with several strategic initiatives to ensure higher productivity and outperform IPM as seen in the past. BSV integration is progressing well with key focus on R&D, improving MR productivity & scaling mandate brands across domestic & international business. During FY25, we've laid a strong foundation to deliver long-term sustainable growth led by four key pillars - steady base business, fast growing specialty chronic, high potential OTC business, and high entry barrier super specialty portfolio of BSV.' Meanwhile, the company's board has approved the incorporation of a wholly owned subsidiary, directly or indirectly, in Sri Lanka (Foreign WOS). Mankind Pharma is one of the largest pharmaceutical company in India, which focuses on the domestic market with its pan-India presence. Mankind Pharma operates at the intersection of the Indian pharmaceutical formulations and consumer healthcare sectors with the aim of providing quality products at affordable prices. The company has 25 manufacturing facilities in India manufacturing a wide range of dosage forms, including tablets, capsules, syrups, vials, ampoules, blow fill seal, soft and hard gels, eye drops, creams, contraceptives and other over-the-counter products. Powered by Capital Market - Live

Net profit of Mankind Pharma declined 10.71% to Rs 420.77 crore in the quarter ended March 2025 as against Rs 471.24 crore during the previous quarter ended March 2024. Sales rose 27.13% to Rs 3079.37 crore in the quarter ended March 2025 as against Rs 2422.24 crore during the previous quarter ended March 2024. For the full year,net profit rose 4.08% to Rs 1990.96 crore in the year ended March 2025 as against Rs 1912.90 crore during the previous year ended March 2024. Sales rose 18.98% to Rs 12207.44 crore in the year ended March 2025 as against Rs 10260.44 crore during the previous year ended March 2024. ParticularsQuarter EndedYear EndedMar. 2025Mar. 2024% Var.Mar. 2025Mar. 2024% Var. Sales3079.372422.24 27 12207.4410260.44 19 OPM %22.1924.20 -24.7224.50 - PBDT746.30671.69 11 3137.552776.36 13 PBT515.43571.91 -10 2516.332397.94 5 NP420.77471.24 -11 1990.961912.90 4 Powered by Capital Market - Live

The Board of Mankind Pharma at its meeting held on 21 May 2025 has approved the incorporation of a wholly owned subsidiary, directly or indirectly, in Sri Lanka (foreign WoS). Powered by Capital Market - Live

Mankind Pharma has allotted 92,512 equity shares under ESOP on 21 May 2025. Consequent to the aforesaid allotment, the paid-up share capital of the Company has increased from 41,25,78,527 equity shares to 41,26,71,039 equity shares having face value of Re. 1/- each.Powered by Capital Market - Live

Mankind Pharma will hold a meeting of the Board of Directors of the Company on 21 May 2025.Powered by Capital Market - Live

However, revenue from operations increased 23.9% year on year (YoY) to Rs 3,230 crore in the third quarter of FY25. Profit before tax was at Rs 497.33 crore in Q3 of FY25, registering a de-growth of 11.56% from Rs 562.32 crore recorded in Q3 FY24. EBITDA grew 36.4% YoY to Rs 833 crore in the December 2024 quarter. EBITDA margin improved to 25.8% in Q3 FY25 as compared to 23.4% recorded in the corresponding quarter previous year. Domestic revenue stood at Rs 2,773 crore in Q3 FY25, up by 15.5% YoY, while export revenue stood at Rs 457 crore, up by 120.8% YoY during the quarter. Export growth was driven by an increase in base business, supported by new launches in the last 12'24 months and consolidation of BSV. During the quarter, the company has launched 1 new product in the US, taking the total launched products to 42. The company's consumer healthcare business reported 30% increase in revenue to Rs 193 crore in Q3 FY25, supported by steady growth across all key brands; strong growth in secondary sales for Manforce Condom, Gas-o-fast and HealthOk of 13%, 28% and 26% YoY respectively and gaining strong traction in recent strategic launches: Manforce Epic (Premium category), Nimulid (Pain Management), etc. Cash flow from operations stood at Rs 460 crore in the third quarter of FY25. Rajeev Juneja, vice chairman & managing director, Mankind Pharma, said, 'We achieved a healthy revenue growth of 24% YoY with a strong adjusted EBITDA margin of 27.7% in Q3 FY25, driven by continued outperformance in chronic, strong recovery in OTC and consolidation of BSV. 30% YoY revenue growth in OTC business supported by strategic initiatives undertaken last year. The integration of BSV is on track, with focus on mandate brands, improving productivity and adopting best practices to ensure long term sustainable growth. 2024 has been a transformative year - now having multiple building blocks ' steady base business, fast growing specialty chronic segment, high potential OTC business, and high-entry barrier super specialty portfolio of BSV.' Mankind Pharma is one of the largest pharmaceutical company in India, which focuses on the domestic market with its Pan India presence.Mankind pharma operates at the intersection of the Indian pharmaceutical formulations and consumer healthcare sectors with the aim of providing quality products at affordable prices. The company has 25 manufacturing facilities in India manufacturing a wide range of dosage forms, including tablets, capsules, syrups, vials, ampoules, blow fill seal, soft and hard gels, eye drops, creams, contraceptives and other over-the-counter products. Powered by Capital Market - Live

Net profit of Mankind Pharma declined 16.20% to Rs 380.23 crore in the quarter ended December 2024 as against Rs 453.76 crore during the previous quarter ended December 2023. Sales rose 23.90% to Rs 3230.00 crore in the quarter ended December 2024 as against Rs 2606.95 crore during the previous quarter ended December 2023. ParticularsQuarter EndedDec. 2024Dec. 2023% Var. Sales3230.002606.95 24 OPM %25.6923.26 - PBDT689.63672.04 3 PBT497.33562.32 -12 NP380.23453.76 -16 Powered by Capital Market - Live

Mankind Pharma will hold a meeting of the Board of Directors of the Company on 23 January 2025.Powered by Capital Market - Live